Sovremennye vozmozhnosti lecheniya retsidivov glioblastom


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

The use of bevacizumab for recurrent or progressive glioblastoma (GBM) affects the time to progression. Impact of bevacizumab on overall survival of patients remains an open question. The article presents the data of own authors’ prospective study with retrospective control, which evaluated the survival of patients with GBM who received bevacizumab in progressive GBM (n=33) and who were not receiving anti-angiogenic therapy (n=73). Main characteristics including age, sex, somatic status, extent of surgical treatment in cohorts were not different from each other. All patients in both cohorts received the same treatment and follow-up to progression. In the main group, bevacizumab was used in relapse or progression in the 2nd or 3rd line therapy at a dose of 7.5 mg /kg every 3 weeks as monotherapy. The median overall survival in the group without bevacizumab was 23 months, in the bevacizumab group - 32 (p=0.012).

Толық мәтін

Рұқсат жабық

Әдебиет тізімі

  1. American Cancer Society: Cancer Facts and Figures 2015. Atlanta, Ga: American Cancer Society, 2015. Available onlineExit Disclaimer. Last accessed July 1, 2015.
  2. Ferlay J., Soerjomataram I., Ervik M., et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide. Lyon, France: International Agency for Research on Cancer, 2013. IARC Cancer Base No. 11. Available online. Exit Disclaimer Last accessed July 22, 2015.
  3. Kristiansen K., Hagen S., Kollevold T., Torvik A., Holme I., Nesbakken R., Hatlevoll R., Lindgren M., Brun A., Lindgren S., Notter G., Andersen A.P., Elgen K. Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer. 1981;47(4):649-52.
  4. Stupp R.,Mason W.P.,vandenBent M.J.,Weller M., Fisher B., Taphoorn M.J., Belanger K., Brandes A.A., Marosi C.,Bogdahn U.,CurschmannJ,Janzer R.C, Ludwin S.K, Gorlia T., Allgeier A, Lacombe D., Cairncross J.G., Eisenhauer E., Mirimanoff R.O. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005;352(10):987-96.
  5. Stummer W., Pichlmeier U., Meinel T., Wiestler O.D., Zanella F., Reulen H.J. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol. 2006;7(5):392-401.
  6. Nieder C., Adam M., Molls M., Grosu A.L. Therapeutic options for recurrent high-grade glioma in adult patients: recent advances. Crit. Rev. Oncol. Hematol. 2006;6:181-93.
  7. Brandes A.A., Fiorentino M.V. The role of chemotherapy in recurrent malignant gliomas: an overview. Cancer Invest. 1996;14:551-59.
  8. Ballman K.V.,Buckner J.C.,Brown P.D.,Giannini C., Flynn P.J., LaPlant B.R., Jaeckle K.A. The relationship between six-month progression-free survival and 12-month overall survival end points for Phase II trials in patients with glioblastoma multiforme. Neuro Oncol. 2007;9:29-38.
  9. Brandes А.А., Tosoni А., Franceschi Е., Blatt V., Santoro A., Faedi M., Amista P., Gardiman M., Labianca R., Bianchini C., Ermani M., Reni M. Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Cancer Chemother. Pharmacol. 2009;64(4):769-75.
  10. Perry J.,Mason W., Belanger K.,Fulton D.,Kavan P., Easaw J., Shields C., Kirby S., Macdonald D.R., Eisenstat D.D., Thiessen B., Forsyth P., Pouliot J.F. The Temozolomide RESCUE study: a Phase II trial of continuous (28/28) dose-intense temozolomide (TMZ) after progression on conventional 5/28 day TMZ in patients with recurrent malignant glioma. Clin. Oncol. 2008;26(Suppl. 15):Abstract 2010
  11. Wick W., Steinbach J.P., Küker W.M., Dichgans J., Bamberg M., Weller M. One week on/one week off: A novel active regimen of temozolomide for recurrent glioblastoma. Neurology. 2004;62:2113-15.
  12. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 1971; 285:1182-86.
  13. Rubenstein J.L., Kim J., Ozawa T., Zhang M., Westphal M., Deen D.F., Shuman MA. AntiVEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia. 2000;2:306-14.
  14. Stefanik D.F., Fellows W.K., Rizkalla L.R., Rizkalla W.M., Stefanik P.P., Deleo A.B., Welch W.C. Monoclonal antibodies to vascular endothelial growth factor (VEGF) and the VEGF receptor, FLT-1, inhibit the growth of C6 glioma in a mouse xenograft. J. Neurooncol. 2001; 55:91-100.
  15. Stark-Vance V. Бевацизумаб and CPT-11 in the treatment of relapsed malignant glioma. Neuro Oncology. 2005;7:369(Abst. 342).
  16. Stark-Vance V. Бевацизумаб and CPT-11 in the treatment of relapsed malignant glioma. Neuro Oncol. 2005;7:369.
  17. Pope W.B., Lai A., Nghiemphu P., Mischel P., Cloughesy T.F. MRI in patients with high-grade gliomas treated with Бевацизумаб and chemotherapy. Neurology. 2006;66:1258-60.
  18. Vredenburgh J.J., Desjardins A., Herndon J.E., Marcello J., Reardon D.A., Quinn J.A., Rich J.N., Sathornsumetee S., Gururangan S., Sampson J., Wagner M., Bailey L., Bigner D.D., Friedman A.H., Friedman H.S. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J. Clin. Oncol. 2007;25:4722-29.
  19. Ali S.A., McHayleh W.M., Ahmad A., Sehgal R., Braffet M., Rahman M., Bejjani G., Friedland D.M. Bevacizumab and irinotecan therapy in glioblastoma multiforme: A series of 13 cases. J. Neurosurg. 2008;109:268-72.
  20. Chamberlain M.C. Role for cytotoxic chemotherapy in patients with recurrent glioblastoma progressing on bevacizumab: A retrospective case series. Expert. Rev. Neurother. 2012; 12:929-36.
  21. Desjardins A., Reardon D.A., Coan A., Marcello J., Herndon J.E. 2nd, Bailey L., Peters K.B., Friedman H.S., Vredenburgh J.J. Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer. 2012;118:1302-12.
  22. Field K.M., Simes J., Wheeler H., Hovey E.J., Nowak A.K., Cher L., Brown C., Livingstone A., Sawkins K., Rosenthal M. A randomized phase II study of carboplatin and bevacizumab in recurrent glioblastoma multiforme (CABARET). J. Clin. Oncol. 2013. (suppl; abstr 2017).
  23. Friedman H.S., Prados M.D., Wen P.Y., Mikkelsen T., Schiff D., Abrey L.E., Yung W.K., Paleologos N., Nicholas M.K., Jensen R., Vredenburgh J., Huang J., Zheng M., Cloughesy T. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol. 2009;27:4733-40.
  24. Gil M.J., de Las Penas R., Reynes G., Balana C., Perez-Segura P., Garcia-Velasco A., Mesia C., Gallego O., Fernandez-Chacon C., Martinez-Garcia M., Herrero A., Andres R., Benavides M., Quintanar T., Perez-Martin X. Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish Neuro-Oncology Research Group (GEINO). Anticancer Drugs. 2012;23:659-65.
  25. Gilbert M.R., Wang M., Aldape K., et al. RTOG 0625: A phase II study of bevacizumab with irinotecan in recurrent glioblastoma (GBM). J. Clin. Oncol. 2009;27:15.
  26. Kreisl T.N., Kim L., Moore K., Duic P., Royce C., Stroud I., Garren N., Mackey M., Butman J.A., Camphausen K., Park J., Albert P.S., Fine H.A. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J. Clin. Oncol. 2009;27:740-45.
  27. Kaloshi G., Brace G., Rroji A., Bushati T., Roci E., Hoxha M., Fejzo G., Petrela M. Bevacizumab alone at 5 mg/kg in an every-3-week schedule for patients with recurrent glioblastomas: A single center experience. Tumori. 2013;99:601-3.
  28. Mоller S., Grunnet K., Hansen S., Schultz H., Holmberg M., Sorensen M., Poulsen H.S., Lassen U. A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy. Acta. Oncol. 2012;51:797-804.
  29. Nagane M., Nishikawa R., Narita Y., Kobayashi H., Takano S., Shinoura N., Aoki T., Sugiyama K., Kuratsu J., Muragaki Y., Sawamura Y., Matsutani M. Phase II study of single-agent bevacizumab in Japanese patients with recurrent malignant glioma. Jpn. J. Clin. Oncol. 2012;42:887-95.
  30. Norden A.D., Young G.S., Setayesh K., Muzikansky A., Klufas R., Ross G.L., Ciampa A.S., Ebbeling L.G., Levy B., Drappatz J., Kesari S., Wen P.Y. Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence. Neurology. 2008;70:779-87.
  31. Raizer J.J., Grimm S., Chamberlain M.C., Nicholas M.K, Chandler J.P., Muro K., Dubner S., Rademaker A.W., Renfrow J., Bredel M. A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas. Cancer. 2010;116:5297-305.
  32. Soffietti R., Trevisan E., Bertero L., Cassoni P., Morra I., Fabrini M.G., Pasqualetti F., Lolli I., Castiglione A., Ciccone G., Ruda R. Bevacizumab and fotemustine for recurrent glioblastoma: A phase II study of AINO (Italian Association of Neuro-Oncology). J. Neurooncol. 2014;116:533-41.
  33. Taal W., Oosterkamp H.M., Walenkamp A.M.E., et al. A randomized phase II study of bevacizumab versus bevacizumab plus lomustine versus lomustine single agent in recurrent glioblastoma: The Dutch BELOB study. J. Clin. Oncol. 2013(suppl; abstr 2001).
  34. Verhoeff J.J.,Lavini C., vanLinde M.E.,Stalpers L.J., Majoie C.B., Reijneveld J.C., van Furth W.R., Richel D.J. Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma. Ann. Oncol. 2010;21:1723-27.
  35. Vredenburgh J.J., Desjardins A., Herndon J.E., Dowel lJ.M., Reardon D.A., Quinn J.A., Rich J.N., Sathornsumetee S., Gururangan S., Wagner M., Bigner D.D., Friedman A.H., Friedman H.S. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin. Cancer Res. 2007;13:1253-59.
  36. Vredenburgh J.J., Desjardins A., Herndon J.E., Marcello J., Reardon D.A., Quinn J.A., Rich J.N., Sathornsumetee S., Gururangan S., Sampson J., Wagner M., Bailey L., Bigner D.D., Friedman A.H., Friedman H.S. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J. Clin. Oncol. 2007;25:4722-29.
  37. Vredenburgh J.J., Wefel J., Cloughesy T., et al. Clinical assessment of corticosteroid use and neurocognitive function in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study. EJC. 2009;7 (Suppl.):495-96.
  38. Sulman E.P., Won M., Blumenthal D.T., et al: Molecular predictors of outcome and response to bevacizumab (BEV) based on analysis of RTOG 0825, a phase III trial comparing chemoradiation (CRT) with and without BEV in patients with newly diagnosed glioblastoma (GBM). J. Clin. Oncol. 2013;31(Suppl. 15s):116s. [Abstr LBA2010].
  39. Plate K.H., Mennel H.D. Vascular morphology and angiogenesis in glial tumors. Exp. Toxicol. Pathol. 1995;47:89-94.
  40. Jain R.K. Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy. Nat. Med. 2001; 7:987-89.
  41. Batchelor T.T., Sorensen A.G., di Tomaso E., Zhang W.T., Duda D.G., Cohen K.S., Kozak K.R., Cahill D.P., Chen P.J., Zhu M., Ancukiewicz M., Mrugala M.M., Plotkin S., Drappatz J., Louis D.N., Ivy P., Scadden D.T., Benner T., Loeffler J.S., Wen P.Y., Jain R.K. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007; 11:83-95.
  42. Sorensen A.G., Emblem K.E., Polaskova P., Jennings D., Kim H., Ancukiewicz M., Wang M., Wen P.Y., Ivy P., Batchelor T.T., Jain R.K. Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. Cancer Res. 2012;72:402-7.
  43. Huang Y., Goel S., Duda D.G., Fukumura D., Jain R.K. Vascular normalization as anemerging strategy to enhance cancer immunotherapy. Cancer Res. 2013;73:2943-48.
  44. Calabrese C., Poppleton H., Kocak M., Hogg T.L., Fuller C., Hamner B., Oh E.Y., Gaber M.W., Finklestein D., Allen M., Frank A., Bayazitov I.T., Zakharenko S.S., Gajjar A., Davidoff A., Gilbertson R.J. A perivascular niche for brain tumor stem cells. Cancer Cell. 2007;11:69-82.
  45. Sulman E.P., Won M., Blumenthal D.T., et al. Molecular predictors of outcome and response to bevacizumab (BEV) based on analysis of RTOG 0825, a phase III trial comparing chemoradiation (CRT) with and without BEV in patients with newly diagnosed glioblastoma (GBM). J. Clin. Oncol. 2013; 31(Suppl. 15s; abstr. LBA2010):116.
  46. Sathornsumetee S., Cao Y., Marcello J.E., Herndon J.E. 2nd, McLendon R.E., Desjardins A., Friedman H.S., Dewhirst M.W., Vredenburgh J.J., Rich J.N. Tumor angiogenic and hypoxic profiles predict adiographic response and survival in malignant astrocytoma patients treated with evacizumab and irinotecan. J. Clin. Oncol. 2008;26:271-78.
  47. Reardon D.A., Desjardins A., Vredenburgh J.J., Gururangan S., Sampson J.H., Sathornsumetee S., McLendon R.E., Herndon J.E. 2nd, Marcello J.E., Norfleet J., Friedman A.H., Bigner D.D., Friedman H.S. Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: A phase II study. Br. J. Cancer. 2009;101:1986-94.
  48. Lu-Emerson C., Snuderl M., Kirkpatrick N.D., Goveia J., Davidson C., Huang Y., Riedemann L., Taylor J., Ivy P., Duda D.G., Ancukiewicz M., Plotkin S.R., Chi A.S., Gerstner E.R., Eichler A.F., Dietrich J., Stemmer-Rachamimov A.O., Batchelor T.T., Jain R.K. Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma. Neuro Oncol. 2013;15:1079-87.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2015

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>